Bcm-95 Curcumin — Why Bioavailability Is Everything
Quick Read Standard curcumin supplements are poorly absorbed by your body because curcumin doesn’t dissolve well in water and is
We write a new article on supplements every day , all detailed, with citations.
Once a week we send an email containing a list of the last 7 days articles. Please sign up and also feel free to share the articles with friends and family who you think might benefit.
Simon Parrott – Vitacuity Ltd
Huperzine A is a compound from Chinese moss that has been approved as an Alzheimer’s treatment since 1996. It works by slowing down an enzyme that breaks down acetylcholine, a brain chemical essential for memory and learning. This allows acetylcholine to remain active in the brain longer, supporting cognitive function when the brain’s memory system is under strain.
Clinical trials in Alzheimer’s patients show measurable improvements in cognition, daily activities, and mood. Animal studies suggest it may do more than just boost acetylcholine temporarily, potentially addressing underlying disease processes like amyloid plaques. However, most research has been done in people with cognitive decline or in animal models, not in healthy adults.
Huperzine A appears safer than similar pharmaceutical drugs, with mostly mild digestive side effects. It works best when your brain is already struggling rather than when it’s functioning optimally. The body gradually restores normal enzyme function once the compound clears, which is a safety advantage. Long-term human data and dosing guidelines for healthy adults remain limited.
Verdict: Huperzine A is one of the more scientifically credible plant-based cognitive support options, with promising evidence particularly for people in midlife experiencing normal age-related memory decline, though larger human studies are needed to confirm benefits in healthy adults.
What if one of the most potent memory-supporting compounds ever studied wasn’t designed in a pharmaceutical lab, but has been growing quietly in Chinese forests for centuries? And what if the way it works isn’t some vague herbal mystery, but a precisely understood biochemical mechanism that modern medicine now uses as a template for Alzheimer’s drugs?
That’s the story of Huperzine A. It’s a compound that most people in the West have never heard of, yet it was approved as a clinical treatment for Alzheimer’s disease in China back in 1996 [3], and researchers are still actively studying it in 2026 [1, 2]. It works on one of the most fundamental levers in your brain’s memory system, a neurotransmitter called acetylcholine, and it does so with a precision that has genuinely surprised scientists. But here’s the honest version: the human trial data, while promising, is still thinner than we’d like, and some of the most exciting findings are still sitting in animal studies. This post will take you through exactly what we know, what we don’t, and what a sensible person might actually do with that information.
Vitacuity has read and analysed over 1.77 million research papers. Here is what the most relevant science on Huperzine A and memory actually shows.
To understand Huperzine A, you first need to understand acetylcholine, and why losing it is such a serious problem for your memory.
Acetylcholine (ACh) is a neurotransmitter: a chemical messenger your brain uses to send signals between nerve cells. It plays a central role in attention, learning and memory formation. When you recall someone’s name, follow a conversation, or learn something new, acetylcholine is doing much of the heavy lifting.
The problem is that your brain also produces an enzyme called acetylcholinesterase (AChE), whose entire job is to break acetylcholine down after it has done its work. In a healthy brain, this cleanup process is well-balanced. But in ageing, and especially in Alzheimer’s disease, something goes wrong. The neurons that produce acetylcholine in a region called the basal forebrain begin to degenerate, acetylcholine levels in the synaptic cleft (the gap between nerve cells) drop significantly, and cognitive function starts to decline [1].
The ‘cholinergic hypothesis’ of Alzheimer’s disease, essentially the idea that depleted acetylcholine is a core driver of cognitive decline, has been a cornerstone of dementia research for decades, and it’s the basis for most currently approved Alzheimer’s medications [1, 6].
Here’s where Huperzine A enters. It’s an alkaloid, a naturally occurring plant compound, first isolated in 1960 from a moss called *Huperzia selago*, and found in particularly high concentrations in *Huperzia serrata*, a club moss used in Chinese traditional medicine [3, 15]. Its mechanism is elegant: it inhibits acetylcholinesterase. In other words, it slows down the enzyme that destroys acetylcholine, allowing more of this memory-critical chemical to remain active in the brain for longer [1, 2].
What makes Huperzine A stand out from other acetylcholinesterase inhibitors (AChEIs) is its selectivity and reversibility. It binds tightly to its target enzyme but doesn’t permanently disable it, the effect wears off, which matters enormously for safety [3, 11]. And compared to similar drugs, it is extraordinarily potent. In direct comparison studies in primates, Huperzine A was found to be 88 times more potent than galantamine (another AChEI used in Alzheimer’s treatment) at inhibiting acetylcholinesterase, with a dose achieving 50% inhibition at just 4.1 micrograms per kilogram, compared to 362 micrograms per kilogram for galantamine [11].
The most fundamental question about any memory-supporting compound is simple: does it actually change brain chemistry in the way it’s supposed to?
For Huperzine A, the answer appears to be yes, and more broadly than researchers initially expected.
A 2026 pharmacokinetic study published in the *Chinese Journal of Natural Medicines* examined exactly how Huperzine A behaves after entering the bloodstream and what it does to acetylcholine in the brain [2]. Using a rat model, researchers found that Huperzine A penetrates the brain rapidly after administration, and, critically, that it elevates acetylcholine concentrations across multiple brain regions simultaneously. The study also found that it modulates several monoamine neurotransmitters (chemicals like dopamine and serotonin that influence mood and cognition), suggesting its effects on brain chemistry are broader than the acetylcholine mechanism alone [2].
An important nuance from this study: a single dose produced a short half-life in the bloodstream, but multiple doses significantly enhanced brain exposure over time, suggesting that consistent supplementation may be more effective than occasional use [2].
Evidence grade: Early stage to promising, this is animal research (rats), but it provides a mechanistic foundation that is consistent with the human clinical findings described below.
Moving from rats to humans, the clinical picture for Huperzine A in Alzheimer’s disease is genuinely encouraging, though with important caveats about sample sizes and study design.
A 2022 review published in *IUBMB Life* examined clinical trial data from the preceding decade on both Ginkgo biloba and Huperzine A in mild to moderate Alzheimer’s disease [9]. The review found that Huperzine A demonstrated measurable improvements across three key domains in AD patients: cognition, activities of daily living, and neuropsychiatric symptoms. The authors noted that these effects are consistent with both cholinergic (acetylcholine-boosting) and neuroprotective mechanisms [9].
A broader 2026 literature review across PubMed, Scopus and Cochrane Library databases, examining clinical data up to 2026, placed Huperzine A in a distinct category from conventional AChEIs like donepezil and rivastigmine [1, 6]. Standard AChEIs produce “cognitive stabilisation” but are described as “strictly symptomatic”, they don’t appear to slow the underlying disease process. Huperzine A, by contrast, was identified as a compound with potential “disease-modifying” properties, meaning it may influence the underlying biological markers of Alzheimer’s, including changes in the cerebrospinal fluid proteins associated with amyloid plaques and tau tangles, not just the symptoms [1, 6].
This is a significant distinction, and one that is generating real scientific interest in 2025–2026 research.
Evidence grade: Promising, human trials exist and show positive effects, but sample sizes have been modest and most trials have focused on Alzheimer’s patients rather than healthy adults seeking cognitive support.
The most exciting, and most preliminary, finding around Huperzine A is that it may do more than temporarily boost acetylcholine. It may actually interfere with the biological processes that drive neurodegeneration.
A 2022 systematic review and meta-analysis published in the *International Journal of Molecular Sciences* examined 16 preclinical studies on rodent Alzheimer’s models [14]. The meta-analysis found that Huperzine A produced four distinct types of measurable effect:
1. Inhibition of acetylcholinesterase (the core mechanism) 2. Enhancement of choline acetyltransferase (ChAT) activity, the enzyme that *makes* acetylcholine, meaning the brain may not only preserve more acetylcholine but produce more of it 3. Measurable improvement in spatial memory tasks (Morris water maze performance) 4. Reduction in soluble amyloid-beta levels in both the cortex and hippocampus, and reduced amyloid plaque counts in the hippocampus
That last point is particularly striking. Amyloid-beta plaques are one of the defining pathological features of Alzheimer’s disease, and the ability to reduce them, not just compensate for their cognitive effects, would mark a meaningful step beyond symptom management [14].
A 2021 review in *Molecules* added further mechanistic detail, identifying that Huperzine A appears to interact with the Wnt signalling pathway, protect mitochondria from oxidative damage, and influence the processing of amyloid precursor protein (APP), the protein that, when misprocessed, generates amyloid-beta [15].
Evidence grade: Early stage, these are rodent studies. The meta-analysis authors themselves note that “due to uneven methodological quality, the results need to be rationally viewed, and extensively repeated.” Translating animal findings to humans is never straightforward. But the consistency and biological plausibility of these findings justify the ongoing human trials.
One of the most intellectually honest findings in this entire body of research comes from a 2011 study published in *Neuropharmacology*, which examined visual recognition memory in six young, healthy pigtail macaques [8].
The researchers gave the monkeys oral Huperzine A and tested them on two memory tasks, one straightforward, one considerably more demanding. The results were nuanced and instructive.
When monkeys were performing close to their maximum (around 90% accuracy), Huperzine A didn’t help, and in some cases slightly reduced performance. But here is the genuinely interesting part: the researchers found a significant negative correlation between baseline performance and the drug’s effect. When animals were performing poorly (55–69% accuracy), Huperzine A improved their scores. The worse the baseline performance, the more room there was for improvement [8].
The researchers drew a clear conclusion: “in a system that functions optimally, the increased availability of acetylcholine does not improve performance or memory.” But when the system is struggling, whether due to difficulty of the task, fatigue, or potentially age-related decline, more acetylcholine appears to help.
This has real-world implications for how we think about Huperzine A as a cognitive support tool. It may be most relevant for people whose acetylcholine system is already under pressure, which, for many adults over 50, is exactly the situation.
Evidence grade: Promising, small study (n=6 monkeys), but the mechanistic logic is sound and the finding has been replicated in its broader principle across multiple research contexts.
Safety matters as much as efficacy. Here, Huperzine A has some genuinely good news to report.
In the 2017 primate study published in the *Journal of Neurochemistry* [11], Huperzine A was directly compared to galantamine and pyridostigmine on both efficacy and behavioural safety. Using an operant time-estimation task, essentially testing whether the animals’ cognitive function was disrupted, the researchers found that Huperzine A was “devoid of behavioural toxicity” even at doses producing significant acetylcholinesterase inhibition. Galantamine, by comparison, showed behavioural toxicity at comparable doses [11].
The known side effects from clinical use are primarily gastrointestinal, dizziness, nausea, and digestive discomfort, consistent with what you’d expect from a cholinergic compound, and similar to effects seen with pharmaceutical AChEIs [3]. These tend to be dose-dependent, meaning lower doses carry lower risk.
Importantly, Huperzine A is a *reversible* inhibitor, it blocks the enzyme temporarily rather than permanently, which means the body can restore normal function once the compound clears. This reversibility is considered a key safety advantage over some synthetic alternatives [3, 11].
Evidence grade: Promising to strong for basic safety profile, the safety data is reasonably consistent across both animal and human studies at standard doses, though long-term human safety data remains limited.
Being honest about the gaps isn’t a sign of weakness in this research, it’s the only way to give you information you can actually trust.
The human trial gap is real. Most of the mechanistic research, the exciting findings about amyloid reduction, Wnt signalling, and mitochondrial protection, comes from rodent studies [14, 15]. Rodents and humans share many biological pathways, but they are not the same. Results that are compelling in rats do not automatically translate to humans, and we need more large, well-designed randomised controlled trials in humans before we can speak with confidence.
The healthy adult data is thin. Almost all clinical work has been done in Alzheimer’s patients or people with diagnosed cognitive impairment. The macaque study [8] is one of the few pieces of research examining effects in cognitively healthy subjects, and it was conducted in six animals. Whether Huperzine A meaningfully supports memory and cognition in healthy adults in their 40s, 50s and 60s is a genuinely open question.
Optimal dosing for different populations is unclear. The 2026 pharmacokinetic modelling study [2] was an attempt to better understand exactly how Huperzine A behaves in the brain at different doses, and the authors noted this remains “poorly characterised.” Dose matters enormously with a compound that works on a precisely tuned neurotransmitter system.
Long-term effects are understudied. Most trials are short-duration. What happens with years of continuous supplementation? We don’t have robust data on this yet.
The disease-modifying claim needs human validation. The suggestion that Huperzine A may modify CSF biomarkers for amyloid and tau [1, 6] is one of the most significant claims in the recent literature, and it’s the one most in need of large-scale, long-term human trials to confirm or refute.
Here’s what a sensible, well-informed person should take from all of this.
Huperzine A has a well-understood mechanism, a reasonable human safety profile at standard doses, and a body of evidence, from cell studies through animal models to human clinical trials, that consistently points in the same direction: it preserves and raises acetylcholine in the brain, and that appears to support cognitive function, particularly when the cholinergic system is under pressure [1, 2, 9, 14, 15].
The most important practical insight comes from the macaque study [8]: Huperzine A may be most useful when your brain’s memory system is already working harder than it should be, whether because of age-related decline, cognitive load, or the early stages of acetylcholine loss that many people begin experiencing in their 40s and 50s. If your brain is running at full capacity, the research suggests you may see minimal benefit. But if there’s a gap to close, and for many of us in midlife and beyond, there is, the evidence suggests it may genuinely help.
Because Huperzine A works on a specific neurotransmitter system (rather than being a simple water-soluble vitamin), it warrants slightly more care than, say, B vitamins, where excess is simply excreted. It is not the kind of compound you take at whatever dose you feel like. Standard supplementation doses used in research have typically been in the range studied in clinical trials for cognitive support, and the side effects (nausea, dizziness) are your body’s signal that you’ve exceeded your personal threshold.
A practical approach for someone in their 40s or 50s interested in long-term cognitive health:
– Consider Huperzine A as part of a broader cholinergic support strategy. It works best when your brain has the raw materials (choline from diet or supplements like alpha-GPC or CDP-choline) alongside the enzyme inhibition it provides. – Start with a lower dose and take note of how you feel. The reversible nature of its mechanism is reassuring, but GI side effects are real and dose-dependent. – Cycling supplementation (taking breaks rather than continuous daily use) is a common practical approach given that AChE can upregulate over time, though the evidence base for specific cycling protocols in humans is limited. – Don’t expect a dramatic overnight effect. The pharmacokinetic research [2] suggests that multiple doses over time increase brain exposure. This is more of a long-term investment than an acute performance booster.
The bottom line: Huperzine A is one of the more scientifically credible plant-derived cognitive support compounds available, with a mechanism that is genuinely well-understood, a safety profile that compares favourably to pharmaceutical AChEIs, and early but consistent evidence of effects that go beyond simple symptom management. The human data needs to grow, but what exists points in a direction worth taking seriously.
[1] Analysis of the Efficacy of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease, Literature Review (2026). DOI: 10.3390/ijms27135733 | https://pubmed.ncbi.nlm.nih.gov/42450004/
[2] Predicting cerebral acetylcholine dynamics with huperzine A pharmacokinetics in blood via mPBPK-PD modeling (2026). DOI: 10.1016/S1875-5364(26)61109-0 | https://pubmed.ncbi.nlm.nih.gov/41781122/
[3] Advances in the structural modification of Alzheimer’s disease drug, Huperzine A (2025). https://pubmed.ncbi.nlm.nih.gov/39637486/
[4] Biotechnological approaches for the production of neuroactive huperzine A (2025). DOI: 10.1016/j.jbiotec.2025.04.020 | https://pubmed.ncbi.nlm.nih.gov/40311807/
[5] Antioxidant, Anti-Inflammatory, and Chemical Composition Analysis of In Vitro *Huperzia serrata* (2026). DOI: 10.3390/molecules31010195 | https://pubmed.ncbi.nlm.nih.gov/41515488/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12787719/
[6] Analysis of the Efficacy of Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease, Literature Review (2026) [second reference to same paper]. DOI: 10.3390/ijms27135733 | https://pubmed.ncbi.nlm.nih.gov/42450004/
[7] Predicting cerebral acetylcholine dynamics with huperzine A pharmacokinetics in blood via mPBPK-PD modeling (2026) [second reference to same paper]. DOI: 10.1016/S1875-5364(26)61109-0 | https://pubmed.ncbi.nlm.nih.gov/41781122/
[8] The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques (2011). *Neuropharmacology*. DOI: 10.1016/j.neuropharm.2010.12.018 | https://pubmed.ncbi.nlm.nih.gov/21185313/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073152/
[9] Ginkgolides and Huperzine A for complementary treatment of Alzheimer’s disease (2022). *IUBMB Life*. DOI: 10.1002/iub.2613 | https://pubmed.ncbi.nlm.nih.gov/35384262/
[10] Huperzine-A Improved Animal Behavior in Cuprizone-Induced Mouse Model by Alleviating Demyelination and Neuroinflammation (2022). *International Journal of Molecular Sciences*. DOI: 10.3390/ijms232416182 | https://pubmed.ncbi.nlm.nih.gov/36555825/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9785798/
[11] Time Course, Behavioral Safety, and Protective Efficacy of Centrally Active Reversible Acetylcholinesterase Inhibitors in Cynomolgus Macaques (2017). *Journal of Neurochemistry*. DOI: 10.1007/s11064-016-2120-9 | https://pubmed.ncbi.nlm.nih.gov/27900576/
[12] The Aqueous Extract of *Humulus japonicus* (2022). *Journal of Medicinal Food*. DOI: 10.1089/jmf.2021.K.0197 | https://pubmed.ncbi.nlm.nih.gov/36178947/
[13] In Silico-Guided Rational Drug Design and Semi-synthesis of C(2)-Functionalized Huperzine A Derivatives as Acetylcholinesterase Inhibitors (2021). *ACS Omega*. DOI: 10.1021/acsomega.1c02875 | https://pubmed.ncbi.nlm.nih.gov/34368579/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8340427/
[14] Disease-Modifying Activity of Huperzine A on Alzheimer’s Disease: Evidence from Preclinical Studies on Rodent Models (2022). *International Journal of Molecular Sciences*. DOI: 10.3390/ijms232315238 | https://pubmed.ncbi.nlm.nih.gov/36499562/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738397/
[15] Huperzine A and Its Neuroprotective Molecular Signaling in Alzheimer’s Disease (2021). *Molecules*. DOI: 10.3390/molecules26216531 | https://pubmed.ncbi.nlm.nih.gov/34770940/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8587556/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Standard curcumin supplements are poorly absorbed by your body because curcumin doesn’t dissolve well in water and is
Quick Read Your gut bacteria and brain communicate through a direct pathway. When you eat prebiotic fibre, your gut bacteria
The nutrients that matter, the forms that work, and the claims to ignore.
